Toll-like receptors as therapeutic targets in gastrointestinal diseases

Bibliography

• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85(2):85-95
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Control of adaptive immune responses by toll-like receptors. Curr Opin Immunol 2002;14(3):380-3
   PubMedGoogle Scholar
• Napolitani G, Rinaldi A, Bertoni F, Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6(8):769-76
   PubMedGoogle Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499-511
   PubMedGoogle Scholar
• Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13(5):816-25
   PubMedGoogle Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
   PubMedGoogle Scholar
• Beutler B. Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 2007;220:113-28
   PubMedGoogle Scholar
• Lotze MT, Zeh HJ, Rubartelli A, The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:60-81
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Pleiotropic function of toll-like receptors. Microbes Infect 2004;6(15):1388-94
   PubMedGoogle Scholar
• Palazzo M, Gariboldi S, Zanobbio L, Cross-talk among toll-like receptors and their ligands. Int Immunol 2008;20(5):709-18
   PubMedGoogle Scholar
• Re F, Strominger JL. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 2004;173(12):7548-55
   PubMedGoogle Scholar
• Re F, Strominger JL. Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology 2004;209(1-2):191-8
   PubMedGoogle Scholar
• Hopkins PA, Sriskandan S. Mammalian toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005;140(3):395-407
   PubMedGoogle Scholar
• Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5(6):446-58
   PubMedGoogle Scholar
• Ortega-Cava CF, Ishihara S, Rumi MA, Strategic compartmentalization of toll-like receptor 4 in the mouse gut. J Immunol 2003;170(8):3977-85
   PubMedGoogle Scholar
• Abreu MT, Thomas LS, Arnold ET, TLR signaling at the intestinal epithelial interface. J Endotoxin Res 2003;9(5):322-30
   PubMedGoogle Scholar
• Abreu MT, Vora P, Faure E, Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167(3):1609-16
   PubMedGoogle Scholar
• Furrie E, MacFarlane S, Thomson G, MacFarlane GT. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005;115(4):565-74
   PubMedGoogle Scholar
• Nomura F, Akashi S, Sakao Y, Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol 2000;164(7):3476-9
   PubMedGoogle Scholar
• Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 2004;5(5):495-502
   PubMedGoogle Scholar
• Mansell A, Smith R, Doyle SL, Suppressor of cytokine signaling 1 negatively regulates toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006;7(2):148-55
   PubMedGoogle Scholar
• Desreumaux P, Dubuquoy L, Nutten S, Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193(7):827-38
   PubMedGoogle Scholar
• Gupta RA, Polk DB, Krishna U, Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappaB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001;276(33):31059-66
   PubMedGoogle Scholar
• Kelly D, Campbell JI, King TP, Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5(1):104-12
   PubMedGoogle Scholar
• Melmed G, Thomas LS, Lee N, Human intestinal epithelial cells are broadly unresponsive to toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003;170(3):1406-15
   PubMedGoogle Scholar
• Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004;126(4):1054-70
   PubMedGoogle Scholar
• Beutler BA. TLRs and innate immunity. Blood 2009;113(7):1399-407
   PubMedGoogle Scholar
• Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann NY Acad Sci 2008;1143:21-34
   PubMed Web of Science ®Google Scholar
• Fukata M, Abreu MT. Role of toll-like receptors in gastrointestinal malignancies. Oncogene 2008;27(2):234-43
   PubMedGoogle Scholar
• Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009;87(2):125-38
   PubMedGoogle Scholar
• Pasare C, Medzhitov R. Control of B-cell responses by toll-like receptors. Nature 2005;438(7066):364-8
   PubMedGoogle Scholar
• Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 2007;44(12):3100-11
   PubMedGoogle Scholar
• Clyne M, Drumm B. Adherence of Helicobacter pylori to primary human gastrointestinal cells. Infect Immun 1993;61(10):4051-7
   PubMedGoogle Scholar
• Rad R, Brenner L, Krug A, Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori. Gastroenterology 2007;133(1):150-163, e153
   PubMedGoogle Scholar
• Smith MF Jr, Mitchell A, Li G, Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappaB activation and chemokine expression by epithelial cells. J Biol Chem 2003;278(35):32552-60
   PubMedGoogle Scholar
• Amedei A, Cappon A, Codolo G, The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest 2006;116(4):1092-101
   PubMedGoogle Scholar
• Mandell L, Moran AP, Cocchiarella A, Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004;72(11):6446-54
   PubMedGoogle Scholar
• Basak C, Pathak SK, Bhattacharyya A, The secreted peptidyl prolyl cis,trans-isomerase HP0175 of Helicobacter pylori induces apoptosis of gastric epithelial cells in a TLR4- and apoptosis signal-regulating kinase 1-dependent manner. J Immunol 2005;174(9):5672-80
   PubMedGoogle Scholar
• Ishihara S, Rumi MA, Kadowaki Y, Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis. J Immunol 2004;173(2):1406-16
   PubMedGoogle Scholar
• Kawahara T, Kuwano Y, Teshima-Kondo S, Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection. J Med Invest 2001;48(3-4):190-7
   PubMedGoogle Scholar
• Takenaka R, Yokota K, Ayada K, Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology 2004;150(Pt 12):3913-22
   PubMedGoogle Scholar
• Rad R, Ballhorn W, Voland P, Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 2009;136(7):2247-57
   PubMedGoogle Scholar
• Uno K, Kato K, Atsumi T, Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007;293(5):G1004-1012
   PubMedGoogle Scholar
• Obonyo M, Sabet M, Cole SP, Deficiencies of myeloid differentiation factor 88, toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect Immun 2007;75(5):2408-14
   PubMedGoogle Scholar
• Gobert AP, Bambou JC, Werts C, Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism. J Biol Chem 2004;279(1):245-50
   PubMedGoogle Scholar
• Anderson AE, Worku ML, Khamri W, TLR9 polymorphisms determine murine lymphocyte responses to Helicobacter: results from a genome-wide scan. Eur J Immunol 2007;37(6):1548-61
   PubMedGoogle Scholar
• Torok AM, Bouton AH, Goldberg JB. Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun 2005;73(3):1523-31
   PubMedGoogle Scholar
• Lee SK, Stack A, Katzowitsch E, Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003;5(15):1345-56
   PubMedGoogle Scholar
• Andersen-Nissen E, Smith KD, Strobe KL, Evasion of toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci USA 2005;102(26):9247-52
   PubMedGoogle Scholar
• Gewirtz AT, Yu Y, Krishna US, Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004;189(10):1914-20
   PubMedGoogle Scholar
• Schmausser B, Andrulis M, Endrich S, Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295(3):179-85
   PubMedGoogle Scholar
• Hishida A, Matsuo K, Goto Y, Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 2009;14(1):47-53
   PubMedGoogle Scholar
• Trejo-De La OA, Torres J, Perez-Rodriguez M, TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008;129(2):333-40
   PubMedGoogle Scholar
• Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007;68(11):901-7
   PubMedGoogle Scholar
• Tahara T, Arisawa T, Wang F, Toll-like receptor 2 (TLR) –196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. Dig Dis Sci 2008;53(4):919-24
   PubMedGoogle Scholar
• Inoue M, Sasazuki S, Wakai K, Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies. Gut 2009;58(10):1323-32
   PubMedGoogle Scholar
• Lee KM, Yeo M, Choue JS, Protective mechanism of epigallocatechin-3-gallate against Helicobacter pylori-induced gastric epithelial cytotoxicity via the blockage of TLR-4 signaling. Helicobacter 2004;9(6):632-42
   PubMedGoogle Scholar
• Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001;2(4):285-6
   PubMedGoogle Scholar
• Chochi K, Ichikura T, Kinoshita M, Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 2008;14(10):2909-17
   PubMedGoogle Scholar
• Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175(12):8242-52
   PubMedGoogle Scholar
• Chang YJ, Wu MS, Lin JT, Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol 2004;66(6):1465-77
   PubMedGoogle Scholar
• Huang B, Zhao J, Shen S, Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007;67(9):4346-52
   PubMedGoogle Scholar
• Santini D, Angeletti S, Ruzzo A, Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008;154(3):360-4
   PubMedGoogle Scholar
• Hold GL, Rabkin CS, Chow WH, A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007;132(3):905-12
   PubMedGoogle Scholar
• Tahara T, Arisawa T, Wang F, Toll-like receptor 2 –196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007;98(11):1790-4
   PubMedGoogle Scholar
• Hietaranta A, Mustonen H, Puolakkainen P, Proinflammatory effects of pancreatic elastase are mediated through TLR4 and NF-kappaB. Biochem Biophys Res Commun 2004;323(1):192-6
   PubMedGoogle Scholar
• Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168(10):5233-9
   PubMedGoogle Scholar
• Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through toll-like receptor 4. J Immunol 2004;172(1):20-4
   PubMedGoogle Scholar
• Song JM, Liu HX, Li Y, Extracellular heat-shock protein 70 aggravates cerulein-induced pancreatitis through toll-like receptor-4 in mice. Chin Med J (Engl) 2008;121(15):1420-5
   PubMedGoogle Scholar
• Ding JL, Li Y, Zhou XY, Potential role of the TLR4/IRAK-4 signaling pathway in the pathophysiology of acute pancreatitis in mice. Inflamm Res 2009;58(11):783-90
   PubMedGoogle Scholar
• Sharif R, Dawra R, Wasiluk K, Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut 2009;58(6):813-9
   PubMedGoogle Scholar
• Sawa H, Ueda T, Takeyama Y, Role of toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg Today 2007;37(10):867-73
   PubMedGoogle Scholar
• Peng Y, Sigua CA, Rideout D, Murr MM. Deletion of toll-like receptor-4 downregulates protein kinase C-ζ and attenuates liver injury in experimental pancreatitis. Surgery 2008;143(5):679-85
   PubMedGoogle Scholar
• Zhang L, Wu HS, Chen Y, Role of nitric oxide in toll-like receptor 2 and 4 mRNA expression in liver of acute hemorrhagic necrotizing pancreatitis rats. World J Gastroenterol 2006;12(3):485-8
   PubMedGoogle Scholar
• Wu HS, Zhang L, Chen Y, Effect of nitric oxide on toll-like receptor 2 and 4 gene expression in rats with acute lung injury complicated by acute hemorrhage necrotizing pancreatitis. Hepatobiliary Pancreat Dis Int 2005;4(4):609-13
   PubMedGoogle Scholar
• Vonlaufen A, Xu Z, Daniel B, Bacterial endotoxin: a trigger factor for alcoholic pancreatitis? Evidence from a novel, physiologically relevant animal model. Gastroenterology 2007;133(4):1293-303
   PubMedGoogle Scholar
• Pastor CM, Pugin J, Kwak B, Role of toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. Crit Care Med 2004;32(8):1759-63
   PubMedGoogle Scholar
• Wang X, Wu L, Wu K, Roles of endotoxin-related signaling molecules in the progression of acute necrotizing pancreatitis in mice. Pancreas 2005;31(3):251-7
   PubMedGoogle Scholar
• Takagi Y, Masamune A, Kume K, Microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene is associated with susceptibility to acute pancreatitis in Japan. Hum Immunol 2009;70(3):200-4
   PubMedGoogle Scholar
• Zeng YJ, Song JM, Li Y, Toll-like receptor 9 is expressed in rat pancreas and is involved in cerulein-induced pancreatitis. Pancreas 2008;36(2):212-4
   PubMedGoogle Scholar
• Matsumura N, Takeyama Y, Ueda T, Decreased expression of Toll-like receptor 2 and 4 on macrophages in experimental severe acute pancreatitis. Kobe J Med Sci 2007;53(5):219-27
   PubMedGoogle Scholar
• Masamune A, Kikuta K, Watanabe T, Pancreatic stellate cells express toll-like receptors. J Gastroenterol 2008;43(5):352-62
   PubMedGoogle Scholar
• Soga Y, Komori H, Miyazaki T, Toll-like receptor 3 signaling induces chronic pancreatitis through the Fas/Fas ligand-mediated cytotoxicity. Tohoku J Exp Med 2009;217(3):175-84
   PubMedGoogle Scholar
• Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of toll-like receptors on pancreatic islets. J Immunol 2004;172(5):3173-80
   PubMedGoogle Scholar
• Schwartz AL, Malgor R, Dickerson E, Phenylmethimazole decreases toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 2009;15(12):4114-22
   PubMedGoogle Scholar
• Pratesi G, Petrangolini G, Tortoreto M, Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65(14):6388-93
   PubMedGoogle Scholar
• Schneider C, Schmidt T, Ziske C, Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004;53(3):355-61
   PubMedGoogle Scholar
• Schmidt J, Welsch T, Jager D, Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007;97(5):598-604
   PubMedGoogle Scholar
• Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991;12(2):162-9
   PubMedGoogle Scholar
• Parlesak A, Schafer C, Schutz T, Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32(5):742-7
   PubMedGoogle Scholar
• Adachi Y, Moore LE, Bradford BU, Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108(1):218-24
   PubMedGoogle Scholar
• Hansen J, Cherwitz DL, Allen JI. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 1994;20(2):461-74
   PubMedGoogle Scholar
• Carithers RL, McClain C. Alcoholic liver disease. In: Feldman L, Friedman L, Brandt J, editors, Sleisenger and fordtran's gastrointestinal and liver disease. Volume 2. 8 edition; 2006. p. 1771-92
   Google Scholar
• Uesugi T, Froh M, Arteel GE, Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001;34(1):101-8
   PubMedGoogle Scholar
• Hritz I, Mandrekar P, Velayudham A, The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008;48(4):1224-31
   PubMedGoogle Scholar
• Seki E, Tsutsui H, Nakano H, Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 2001;166(4):2651-7
   PubMedGoogle Scholar
• Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130(6):1886-900
   PubMedGoogle Scholar
• Uesugi T, Froh M, Arteel GE, Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002;168(6):2963-9
   PubMedGoogle Scholar
• Yin M, Bradford BU, Wheeler MD, Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001;166(7):4737-42
   PubMedGoogle Scholar
• Gustot T, Lemmers A, Moreno C, Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006;43(5):989-1000
   PubMedGoogle Scholar
• Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007;102(7):1510-7
   PubMedGoogle Scholar
• Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005;42(Suppl 1):S85-92
   PubMedGoogle Scholar
• Nanji AA, Khwaja S, Tahan SR, Sadrzadeh SM. Plasma levels of a novel noncyclooxygenase-derived prostanoid (8-isoprostane) correlate with severity of liver injury in experimental alcoholic liver disease. J Pharmacol Exp Ther 1994;269(3):1280-5
   PubMedGoogle Scholar
• Valenti L, Ludovica Fracanzani A, Fargion S. The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? Semin Immunopathol 2009;31(3):359-69
   PubMedGoogle Scholar
• Kawaratani H, Tsujimoto T, Kitazawa T, Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol 2008;14(43):6655-61
   PubMedGoogle Scholar
• Brun P, Castagliuolo I, Di Leo V, Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292(2):G518-525
   PubMedGoogle Scholar
• Cani PD, Amar J, Iglesias MA, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56(7):1761-72
   PubMedGoogle Scholar
• Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005;29(11 Suppl):140S-5S
   PubMedGoogle Scholar
• Rivera CA, Adegboyega P, Van Rooijen N, Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47(4):571-9
   PubMedGoogle Scholar
• Cani PD, Bibiloni R, Knauf C, Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57(6):1470-81
   PubMedGoogle Scholar
• Membrez M, Blancher F, Jaquet M, Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22(7):2416-26
   PubMedGoogle Scholar
• Li Z, Yang S, Lin H, Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37(2):343-50
   PubMedGoogle Scholar
• Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38(5):681-7
   PubMedGoogle Scholar
• Cooper A, Tal G, Lider O, Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 2005;175(5):3165-76
   PubMedGoogle Scholar
• Chen Z, Cheng Y, Xu Y, Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008;128(3):400-8
   PubMedGoogle Scholar
• Wu J, Meng Z, Jiang M, Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49(4):1132-40
   PubMedGoogle Scholar
• Visvanathan K, Skinner NA, Thompson AJ, Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007;45(1):102-10
   PubMedGoogle Scholar
• Riordan SM, Skinner N, Kurtovic J, Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 2006;13(8):972-4
   PubMedGoogle Scholar
• McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000;74(5):2255-64
   PubMedGoogle Scholar
• Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79(11):7269-72
   PubMedGoogle Scholar
• Wu J, Lu M, Meng Z, Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007;46(6):1769-78
   PubMedGoogle Scholar
• Cooper CL, Davis HL, Morris ML, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J Clin Immunol 2004;24(6):693-701
   PubMedGoogle Scholar
• Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem Biophys Res Commun 2007;361(2):537-42
   PubMedGoogle Scholar
• Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005;23(45):5263-70
   PubMedGoogle Scholar
• Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007;82(3):479-87
   PubMedGoogle Scholar
• Dolganiuc A, Norkina O, Kodys K, Viral and host factors induce macrophage activation and loss of Toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133(5):1627-36
   PubMedGoogle Scholar
• Dolganiuc A, Oak S, Kodys K, Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004;127(5):1513-24
   PubMedGoogle Scholar
• Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128(2):133-47
   PubMedGoogle Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5(3):215-29
   PubMedGoogle Scholar
• Li K, Foy E, Ferreon JC, Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102(8):2992-7
   PubMedGoogle Scholar
• Otsuka M, Kato N, Moriyama M, Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005;41(5):1004-12
   PubMedGoogle Scholar
• Abe T, Kaname Y, Hamamoto I, Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007;81(17):8953-66
   PubMedGoogle Scholar
• Miyazaki M, Kanto T, Inoue M, Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of toll-like receptors and retinoic acid inducible gene-I. J Med Virol 2008;80(6):980-8
   PubMedGoogle Scholar
• Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008;47(2):385-95
   PubMedGoogle Scholar
• Yonkers NL, Rodriguez B, Milkovich KA, TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection. J Immunol 2007;178(7):4436-44
   PubMedGoogle Scholar
• Machida K, Cheng KT, Sung VM, Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006;80(2):866-74
   PubMedGoogle Scholar
• Broering R, Wu J, Meng Z, Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914-22
   PubMedGoogle Scholar
• Horsmans Y, Berg T, Desager JP, Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005;42(3):724-31
   PubMedGoogle Scholar
• McHutchison JG, Bacon BR, Gordon SC, Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46(5):1341-9
   PubMedGoogle Scholar
• Chan CC, Hwang SJ, Lee FY, Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997;32(9):942-6
   PubMedGoogle Scholar
• Grinko I, Geerts A, Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J Hepatol 1995;23(4):449-58
   PubMedGoogle Scholar
• Lin RS, Lee FY, Lee SD, Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22(2):165-72
   PubMedGoogle Scholar
• Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol 1995;23(4):396-402
   PubMedGoogle Scholar
• Isayama F, Hines IN, Kremer M, LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1318-1328
   PubMedGoogle Scholar
• Seki E, De Minicis S, Osterreicher CH, TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13(11):1324-32
   PubMedGoogle Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115(2):209-18
   PubMedGoogle Scholar
• Paik YH, Schwabe RF, Bataller R, Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37(5):1043-55
   PubMedGoogle Scholar
• Li Y, Chang M, Abar O, Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 2009;51(4):750-7
   PubMedGoogle Scholar
• Guo J, Loke J, Zheng F, Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009;49(3):960-8
   PubMedGoogle Scholar
• Huang H, Shiffman ML, Friedman S, A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007;46(2):297-306
   PubMedGoogle Scholar
• Schnabl B, Brandl K, Fink M, A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun 2008;375(2):210-4
   PubMedGoogle Scholar
• Gabele E, Muhlbauer M, Dorn C, Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008;376(2):271-6
   PubMedGoogle Scholar
• Watanabe A, Hashmi A, Gomes DA, Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007;46(5):1509-18
   PubMedGoogle Scholar
• Lin CY, Tsai IF, Ho YP, Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007;46(5):816-26
   PubMedGoogle Scholar
• Testro AG, Gow PJ, Angus PW, Effects of antibiotics on expression and function of toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol 2009: published online 19 November 2009, doi: 10.1016/j.jhep.2009.11.006
   PubMedGoogle Scholar
• Pimentel-Nunes P, Roncon-Albuquerque R Jr, Gonçalves N, Attenuation of toll-Like receptor 2 activation in alcoholic chronic liver disease: a mechanism for acquired immunodeficiency? Gastroenterology 2009;136(Suppl 5):A-451
   Google Scholar
• Riordan SM, Skinner N, Nagree A, Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003;37(5):1154-64
   PubMedGoogle Scholar
• Chen A, Zheng S. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol 2008;153(3):557-67
   PubMedGoogle Scholar
• Lubbad A, Oriowo MA, Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009;322(1-2):127-35
   PubMedGoogle Scholar
• Gradisar H, Keber MM, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 2007;82(4):968-74
   PubMedGoogle Scholar
• Stadlbauer V, Mookerjee RP, Hodges S, Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008;48(6):945-51
   PubMedGoogle Scholar
• Rutenburg AM, Sonnenblick E, Koven I, The role of intestinal bacteria in the development of dietary cirrhosis in rats. J Exp Med 1957;106(1):1-14
   PubMedGoogle Scholar
• Liu X, Xu Q, Chen W, Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of nonmethylated CpG DNA. Oncol Rep 2009;21(4):941-7
   PubMedGoogle Scholar
• Yoneda K, Sugimoto K, Shiraki K, Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 2008;33(5):929-36
   PubMedGoogle Scholar
• Khvalevsky E, Rivkin L, Rachmilewitz J, TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007;100(5):1301-12
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16
   PubMed Web of Science ®Google Scholar
• Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002;139(4):234-43
   PubMedGoogle Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441(7092):431-6
   PubMed Web of Science ®Google Scholar
• Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008;48(2):380-1
   PubMedGoogle Scholar
• Naugler WE, Sakurai T, Kim S, Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317(5834):121-4
   PubMedGoogle Scholar
• Sakurai T, He G, Matsuzawa A, Hepatocyte necrosis induced by oxidative stress and IL-1alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14(2):156-65
   PubMedGoogle Scholar
• Machida K, Tsukamoto H, Mkrtchyan H, Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 2009;106(5):1548-53
   PubMedGoogle Scholar
• Wang AP, Migita K, Ito M, Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005;25(1):85-91
   PubMedGoogle Scholar
• Shimoda S, Harada K, Niiro H, Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008;47(3):958-65
   PubMedGoogle Scholar
• Takii Y, Nakamura M, Ito M, Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005;85(7):908-20
   PubMedGoogle Scholar
• Honda Y, Yamagiwa S, Matsuda Y, Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis. J Hepatol 2007;47(3):404-11
   PubMedGoogle Scholar
• Kikuchi K, Lian ZX, Kimura Y, Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 2005;24(4):347-52
   PubMedGoogle Scholar
• Kikuchi K, Lian ZX, Yang GX, Bacterial CpG induces hyper-IgM production in CD27+ memory B cells in primary biliary cirrhosis. Gastroenterology 2005;128(2):304-12
   PubMedGoogle Scholar
• Mao TK, Lian ZX, Selmi C, Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 2005;42(4):802-8
   PubMedGoogle Scholar
• Harada K, Isse K, Kamihira T, Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 2005;41(6):1329-38
   PubMedGoogle Scholar
• Shen XD, Ke B, Zhai Y, Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl 2007;13(10):1435-43
   PubMedGoogle Scholar
• Wang H, Li ZY, Wu HS, Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway. Chin Med J (Engl) 2007;120(6):509-14
   PubMedGoogle Scholar
• Zhai Y, Qiao B, Shen XD, Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation 2008;85(7):1016-22
   PubMedGoogle Scholar
• Wu HS, Zhang JX, Wang L. Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2004;3(2):250-3
   PubMedGoogle Scholar
• Zhai Y, Shen XD, O'Connell R, Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004;173(12):7115-9
   PubMedGoogle Scholar
• Galloway E, Shin T, Huber N, Activation of hepatocytes by extracellular heat shock protein 72. Am J Physiol Cell Physiol 2008;295(2):C514-520
   PubMedGoogle Scholar
• Zhang JX, Wu HS, Wang H, Protection against hepatic ischemia/reperfusion injury via downregulation of toll-like receptor 2 expression by inhibition of Kupffer cell function. World J Gastroenterol 2005;11(28):4423-6
   PubMedGoogle Scholar
• Wang H, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur J Pharmacol 2006;534(1-3):194-201
   PubMedGoogle Scholar
• Yao XM, Chen H, Li Y. Protective effect of bicyclol on liver injury induced by hepatic warm ischemia/reperfusion in rats. Hepatol Res 2009;39(8):833-42
   PubMedGoogle Scholar
• Jin X, Wang L, Wu HS, N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 2007;6(3):284-9
   PubMedGoogle Scholar
• Testro AG, Visvanathan K, Angus PW, Gow PJ. Down-regulation of the toll-like receptor 4 dependent innate immune response protects against the development of acute allograft rejection in liver transplant recipients. J Gastroenterol Hepatol 2008;23(Suppl 4):A-251
   Google Scholar
• Imaeda AB, Watanabe A, Sohail MA, Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest 2009;119(2):305-14
   PubMedGoogle Scholar
• Yohe HC, O'Hara KA, Hunt JA, Involvement of toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1269-1279
   PubMedGoogle Scholar
• Deng JF, Geng L, Qian YG, The role of toll-like receptors 2 and 4 in acute allograft rejection after liver transplantation. Transplant Proc 2007;39(10):3222-4
   PubMedGoogle Scholar
• Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. Therapeutic approach to regulate innate immune response by toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol 2009;24(6):1089-94
   PubMed Web of Science ®Google Scholar
• Thomas KE, Sapone A, Fasano A, Vogel SN. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol 2006;176(4):2512-21
   PubMedGoogle Scholar
• Zanoni G, Navone R, Lunardi C, In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006;3(9):e358. Published online 19 September 2006, doi: 10.1371/journal.pmed.0030358
   PubMedGoogle Scholar
• Szebeni B, Veres G, Dezsofi A, Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr 2007;45(2):187-93
   PubMedGoogle Scholar
• Kato S, Ito Y, Nishio H, Increased susceptibility of small intestine to NSAID-provoked ulceration in rats with adjuvant-induced arthritis: involvement of enhanced expression of TLR4. Life Sci 2007;81(16):1309-16
   PubMedGoogle Scholar
• Watanabe T, Higuchi K, Kobata A, Non-steroidal anti-inflammatory drug-induced small intestinal damage is toll-like receptor 4 dependent. Gut 2008;57(2):181-7
   PubMedGoogle Scholar
• Watanabe T, Nishio H, Tanigawa T, Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009;297(3):G506-513
   PubMedGoogle Scholar
• Waselenko JK, Macvittie TJ, Blakely WF, Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004;140(12):1037-51
   PubMedGoogle Scholar
• Burdelya LG, Krivokrysenko VI, Tallant TC, An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320(5873):226-30
   PubMedGoogle Scholar
• Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004;127(1):224-38
   PubMedGoogle Scholar
• Gibson DL, Ma C, Rosenberger CM, Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during Citrobacter rodentium-induced colitis. Cell Microbiol 2008;10(2):388-403
   PubMedGoogle Scholar
• Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132(4):1359-74
   PubMedGoogle Scholar
• Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009;137(1):209-20
   PubMedGoogle Scholar
• Pierik M, Joossens S, Van Steen K, Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006;12(1):1-8
   PubMedGoogle Scholar
• Yang Z, Fuss IJ, Watanabe T, NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction. Gastroenterology 2007;133(5):1510-21
   PubMedGoogle Scholar
• Watanabe T, Kitani A, Murray PJ, Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006;25(3):473-85
   PubMedGoogle Scholar
• Hausmann M, Kiessling S, Mestermann S, Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122(7):1987-2000
   PubMedGoogle Scholar
• Szebeni B, Veres G, Dezsofi A, Increased expression of toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008;151(1):34-41
   PubMedGoogle Scholar
• Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006;103(18):7048-53
   PubMedGoogle Scholar
• Muratov V, Ulfgren AK, Engstrom M, Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 2008;43(4):277-82
   PubMedGoogle Scholar
• Heimesaat MM, Fischer A, Jahn HK, Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut 2007;56(7):941-8
   PubMedGoogle Scholar
• Heimesaat MM, Fischer A, Siegmund B, Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One 2007;2(7):e662. Published online 25 July 2007, doi: 10.1371/journal.pone.0000662
   PubMedGoogle Scholar
• Canto E, Ricart E, Monfort D, TNFalpha production to TLR2 ligands in active IBD patients. Clin Immunol 2006;119(2):156-65
   PubMedGoogle Scholar
• Arranz A, Abad C, Juarranz Y, Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann NY Acad Sci 2006;1070:129-34
   PubMedGoogle Scholar
• Arranz A, Juarranz Y, Leceta J, VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 2008;29(6):948-56
   PubMedGoogle Scholar
• Fukata M, Michelsen KS, Eri R, Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005;288(5):G1055-1065
   PubMedGoogle Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118(2):229-41
   PubMedGoogle Scholar
• Araki A, Kanai T, Ishikura T, MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005;40(1):16-23
   PubMedGoogle Scholar
• Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006;25(2):319-29
   PubMedGoogle Scholar
• Matharu KS, Mizoguchi E, Cotoner CA, Toll-like receptor 4-mediated regulation of spontaneous Helicobacter-dependent colitis in IL-10-deficient mice. Gastroenterology 2009;137(4):1380-90
   PubMedGoogle Scholar
• Fort MM, Mozaffarian A, Stover AG, A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174(10):6416-23
   PubMed Web of Science ®Google Scholar
• Teng X, Xu LF, Zhou P, Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. Inflammation 2009;32(2):120-9
   PubMedGoogle Scholar
• Tuin A, Poelstra K, De Jager-Krikken A, Role of alkaline phosphatase in colitis in man and rats. Gut 2009;58(3):379-87
   PubMedGoogle Scholar
• Lee JH, Lee B, Lee HS, Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis. Int J Colorectal Dis 2009;24(2):231-7
   PubMedGoogle Scholar
• Eun CS, Han DS, Lee SH, Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on toll-like receptor pathway. Dig Dis Sci 2006;51(4):693-7
   PubMedGoogle Scholar
• Morimoto M, Watanabe T, Yamori M, Isoflavones regulate innate immunity and inhibit experimental colitis. J Gastroenterol Hepatol 2009;24(6):1123-9
   PubMedGoogle Scholar
• Ungaro R, Fukata M, Hsu D, A novel toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009;296(6):G1167-1179
   PubMed Web of Science ®Google Scholar
• Hume GE, Fowler EV, Doecke J, Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. Inflamm Bowel Dis 2008;14(5):585-90
   PubMedGoogle Scholar
• Browning BL, Huebner C, Petermann I, Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007;102(11):2504-12
   PubMedGoogle Scholar
• De Jager PL, Franchimont D, Waliszewska A, The role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007;8(5):387-97
   PubMedGoogle Scholar
• Gazouli M, Mantzaris G, Kotsinas A, Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005;11(5):681-5
   PubMedGoogle Scholar
• Franchimont D, Vermeire S, El Housni H, Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53(7):987-92
   PubMedGoogle Scholar
• Ouburg S, Mallant-Hent R, Crusius JB, The toll-like receptor 4 (TLR4) Asp299Gly polymorphism is associated with colonic localisation of Crohn's disease without a major role for the Saccharomyces cerevisiae mannan-LBP-CD14-TLR4 pathway. Gut 2005;54(3):439-440
   PubMedGoogle Scholar
• Vijay-Kumar M, Wu H, Aitken J, Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007;13(7):856-64
   PubMedGoogle Scholar
• Zhou R, Wei H, Sun R, Tian Z. Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. J Immunol 2007;178(7):4548-56
   PubMedGoogle Scholar
• Zhou R, Wei H, Sun R, NKG2D recognition mediates toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc Natl Acad Sci USA 2007;104(18):7512-5
   PubMedGoogle Scholar
• Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68(12):7010-7
   PubMedGoogle Scholar
• Gewirtz AT, Navas TA, Lyons S, Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167(4):1882-5
   PubMedGoogle Scholar
• Rhee SH, Im E, Riegler M, Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA 2005;102(38):13610-5
   PubMedGoogle Scholar
• Carvalho FA, Barnich N, Sauvanet P, Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis 2008;14(8):1051-60
   PubMedGoogle Scholar
• Lodes MJ, Cong Y, Elson CO, Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113(9):1296-306
   PubMedGoogle Scholar
• Papadakis KA, Yang H, Ippoliti A, Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007;13(5):524-30
   PubMedGoogle Scholar
• Gewirtz AT, Vijay-Kumar M, Brant SR, Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006;290(6):G1157-1163
   PubMedGoogle Scholar
• Vijay-Kumar M, Sanders CJ, Taylor RT, Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007;117(12):3909-21
   PubMedGoogle Scholar
• Steenholdt C, Andresen L, Pedersen G, Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease. Scand J Gastroenterol 2009;44(2):195-204
   PubMedGoogle Scholar
• Saruta M, Targan SR, Mei L, High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females. Inflamm Bowel Dis 2009;15(3):321-7
   PubMedGoogle Scholar
• Rachmilewitz D, Karmeli F, Takabayashi K, Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122(5):1428-41
   PubMedGoogle Scholar
• Katakura K, Lee J, Rachmilewitz D, Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005;115(3):695-702
   PubMedGoogle Scholar
• Obermeier F, Strauch UG, Dunger N, In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005;54(10):1428-36
   PubMedGoogle Scholar
• Rachmilewitz D, Katakura K, Karmeli F, Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126(2):520-8
   PubMedGoogle Scholar
• Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann NY Acad Sci 2006;1072:351-5
   PubMedGoogle Scholar
• Rachmilewitz D, Karmeli F, Shteingart S, Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis 2006;12(5):339-45
   PubMedGoogle Scholar
• Obermeier F, Dunger N, Deml L, CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol 2002;32(7):2084-92
   PubMedGoogle Scholar
• Mane J, Pedrosa E, Loren V, Partial replacement of dietary (n-6) fatty acids with medium-chain triglycerides decreases the incidence of spontaneous colitis in interleukin-10-deficient mice. J Nutr 2009;139(3):603-10
   PubMedGoogle Scholar
• Obermeier F, Dunger N, Strauch UG, CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology 2005;129(3):913-27
   PubMedGoogle Scholar
• Torok HP, Glas J, Tonenchi L, Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004;127(1):365-6
   PubMedGoogle Scholar
• Torok HP, Glas J, Endres I, Epistasis between toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009;104(7):1723-33
   PubMedGoogle Scholar
• Lee J, Mo JH, Katakura K, Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8(12):1327-36
   PubMedGoogle Scholar
• Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 2009;14(2):248-72
   PubMedGoogle Scholar
• Rutter M, Saunders B, Wilkinson K, Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126(2):451-9
   PubMedGoogle Scholar
• Laqueur GL, Matsumoto H, Yamamoto RS. Comparison of the carcinogenicity of methylazoxymethanol- beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J Natl Cancer Inst 1981;67(5):1053-5
   PubMedGoogle Scholar
• Swidsinski A, Khilkin M, Kerjaschki D, Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115(2):281-6
   PubMedGoogle Scholar
• Uronis JM, Muhlbauer M, Herfarth HH, Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4(6):e6026. Published online 24 June 2009, doi: 10.1371/journal.pone.0006026
   PubMedGoogle Scholar
• Fukata M, Chen A, Klepper A, Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131(3):862-77
   PubMedGoogle Scholar
• Fukata M, Chen A, Vamadevan AS, Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133(6):1869-81
   PubMedGoogle Scholar
• Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 2009, 29(7):2473-8
   PubMedGoogle Scholar
• Sun Q, Liu Q, Zheng Y, Cao X. Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol 2008;45(10):2929-36
   PubMedGoogle Scholar
• Sun Q, Zheng Y, Liu Q, Cao X. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. Int Immunopharmacol 2008;8(13-14):1854-8
   PubMedGoogle Scholar
• Earl TM, Nicoud IB, Pierce JM, Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16(4):1043-50
   PubMedGoogle Scholar
• Huang B, Zhao J, Li H, Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65(12):5009-14
   PubMedGoogle Scholar
• Yoshioka T, Morimoto Y, Iwagaki H, Bacterial lipopolysaccharide induces transforming growth factor beta and hepatocyte growth factor through toll-like receptor 2 in cultured human colon cancer cells. J Int Med Res 2001;29(5):409-20
   PubMedGoogle Scholar
• Boraska Jelavic T, Barisic M, Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006;70(2):156-60
   PubMedGoogle Scholar
• Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008;135(2):518-28
   PubMedGoogle Scholar
• Rayburn ER, Wang W, Zhang R, Wang H. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 2007;30(6):1511-9
   PubMedGoogle Scholar
• Kim HA, Ko HM, Ju HW, CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. Cancer Lett 2009;274(1):160-4
   PubMedGoogle Scholar
• Damiano V, Caputo R, Garofalo S, TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci USA 2007;104(30):12468-73
   PubMed Web of Science ®Google Scholar
• Damiano V, Caputo R, Bianco R, Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006;12(2):577-83
   PubMed Web of Science ®Google Scholar
• Bertin S, Samson M, Pons C, Comparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivo. Mol Cell Proteomics 2008;7(12):2311-22
   PubMedGoogle Scholar
• Jilling T, Simon D, Lu J, The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol 2006;177(5):3273-82
   PubMedGoogle Scholar
• Qi W, Ebbert KV, Craig AW, Absence of Fer protein tyrosine kinase exacerbates endotoxin induced intestinal epithelial barrier dysfunction in vivo. Gut 2005;54(8):1091-7
   PubMedGoogle Scholar
• Lu J, Jilling T, Li D, Caplan MS. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007;61(4):427-32
   PubMedGoogle Scholar
• Leaphart CL, Cavallo J, Gribar SC, A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol 2007;179(7):4808-20
   PubMedGoogle Scholar
• Gribar SC, Sodhi CP, Richardson WM, Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol 2009;182(1):636-46
   PubMedGoogle Scholar